The involvement of RUNX2 in PI3K/Akt signaling is well-known in myeloid malignancies (Khalaj et al., 2014), and the authors demonstrated that miR-338-3p significantly suppressed both RUNX2 mRNA and protein. Here, RUNX2 is linked to myeloid neoplasm.